RCKT
Companies
NASDAQ
Rocket Pharmaceuticals Inc.
Health Care
$2.83
-$9.74 (-77.49%)
Price Chart
Overview
About RCKT
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
Market Cap
$2.1B
Volume
9.4M
Avg. Volume
9.7M
P/E Ratio
-2.6145039
Dividend Yield
0.00%
Employees
236.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.42
High Correlation
Volatility
High (0.54)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, RCKT shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$2.1B
Volume9.4M
P/E Ratio-2.61
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 9, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025